Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy (HODGSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03535948
Recruitment Status : Not yet recruiting
First Posted : May 24, 2018
Last Update Posted : May 24, 2018
Sponsor:
Information provided by (Responsible Party):
Central Hospital, Nancy, France

Brief Summary:
Outcome of Hodgkin lymphoma patients over than 60 years treated by chemotherapy and/or radiotherapy: retrospective analysis.

Condition or disease
Hodgkin Lymphoma, Adult

Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Outcome of Hodgkin Lymphoma Patients Over Than 60 Years Treated by Chemotherapy and/or Radiotherapy: a Retrospective Study
Estimated Study Start Date : May 2018
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: Time between diagnosis and progression or death - up to 100 weeks ]
    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All Hodgkin lymphoma patients over 60 years treated between 2000 and 2013 by chemotherapy and/or radiotherapy in two university hospitals in France
Criteria

Inclusion Criteria:

  • Patients over than 60 years
  • Newly diagnosed Hodgkin lymphoma

Exclusion Criteria:

  • Data not available

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03535948


Contacts
Layout table for location contacts
Contact: Aurore Perrot +3383155166 au.perrot@chru-nancy.fr

Locations
Layout table for location information
France
CHU Dijon Not yet recruiting
Dijon, France, 21000
Contact: Cédric Rossi       cedric.rossi66@gmail.com   
CHRU Nancy Not yet recruiting
Vandœuvre-lès-Nancy, France, 54500
Contact: Aurore PERROT       au.perrot@chru-nancy.fr   
Contact: Lauriane FILLIATRE-CLEMENT       la.clement@chru-nancy.fr   
Sponsors and Collaborators
Central Hospital, Nancy, France
Investigators
Layout table for investigator information
Principal Investigator: Lauriane Filliatre-Clement CHRU Nancy

Layout table for additonal information
Responsible Party: Central Hospital, Nancy, France
ClinicalTrials.gov Identifier: NCT03535948     History of Changes
Other Study ID Numbers: PSS2016/hodgSA-CLEMENT-F/AS
First Posted: May 24, 2018    Key Record Dates
Last Update Posted: May 24, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases